| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51a0c49e5390c69aa92b87c3a892344c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-62 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-62 |
| filingDate |
1994-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1995-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f812f5927b03a18cf102b8b5f285eb09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b02edb26913649f1bb37c77c42b0dc58 |
| publicationDate |
1995-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5399721-A |
| titleOfInvention |
Synthesis of optically pure 4-aryl-2-hydroxytetronic acids |
| abstract |
The present invention relates to a method for synthesis of optically pure stereogenically labile 4-aryl-2-hydroxytetronic acids from an optically pure aldehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase. the invention further relates to the pharmaceutical use of such compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6265436-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9532194-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6262073-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5656662-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6005000-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6136832-A |
| priorityDate |
1990-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |